{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:15:04Z","timestamp":1788970504235,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24592689"],"award-info":[{"award-number":["24592689"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.oret.2023.06.002","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:23:35Z","timestamp":1686183815000},"page":"869-878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-VEGF Treatment Strategies for 3 Subtypes of Neovascular Age-Related Macular Degeneration in a Clinical Setting"],"prefix":"10.1016","volume":"7","author":[{"given":"Keisuke","family":"Yoneda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9913-1905","authenticated-orcid":false,"given":"Tsutomu","family":"Yasukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7107-6366","authenticated-orcid":false,"given":"Yuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Jujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Wakuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4813-672X","authenticated-orcid":false,"given":"Yoshinori","family":"Mitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9350-6809","authenticated-orcid":false,"given":"Aki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineo","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0807-8817","authenticated-orcid":false,"given":"Fumi","family":"Gomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2023.06.002_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.oret.2023.06.002_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.oret.2023.06.002_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"issue":"suppl 1","key":"10.1016\/j.oret.2023.06.002_bib4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/IAE.0b013e31823f9b3b","article-title":"Retinal angiomatous proliferation in age-related macular degeneration. 2001","volume":"32","author":"Yannuzzi","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.oret.2023.06.002_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/ceo.13114","article-title":"Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of \u2018expanded spectra\u2019 - a review","volume":"46","author":"Dansingani","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.survophthal.2003.10.007","article-title":"Polypoidal choroidal vasculopathy","volume":"49","author":"Ciardella","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ophtha.2013.08.035","article-title":"Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration","volume":"121","author":"Chang","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2023.06.002_bib8","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10384-023-00981-0","article-title":"Subtype prevalence and baseline visual acuity by age in Japanese patients with neovascular age-related macular degeneration","volume":"67","author":"Sawada","year":"2023","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00006982-200509000-00005","article-title":"Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation","volume":"25","author":"Gross","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.oret.2023.06.002_bib12","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1017\/S0950268816003174","article-title":"Association of cigarette smoking with a past history and incidence of herpes zoster in the general Japanese population: the SHEZ Study","volume":"145","author":"Ban","year":"2017","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.oret.2023.06.002_bib13","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1001\/archopht.117.11.1503","article-title":"Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration","volume":"117","author":"Yannuzzi","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","article-title":"Clinical characteristics of exudative age-related macular degeneration in Japanese patients","volume":"144","author":"Maruko","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib15","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/archopht.117.8.1035","article-title":"Idiopathic polypoidal choroidal vasculopathy in Japanese patients","volume":"117","author":"Uyama","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00006982-200110000-00003","article-title":"Retinal angiomatous proliferation in age-related macular degeneration","volume":"21","author":"Yannuzzi","year":"2001","journal-title":"Retina"},{"key":"10.1016\/j.oret.2023.06.002_bib17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/08820538.2018.1506483","article-title":"Prevalence and risk factors for polypoidal choroidal vasculopathy in a general Japanese population: the Hisayama study","volume":"33","author":"Fujiwara","year":"2018","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib18","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1097\/IAE.0000000000001872","article-title":"Prevalence of polypoidal choroidal vasculopathy in white patients with exudative age-related macular degeneration: systematic review and meta-analysis","volume":"38","author":"Lorentzen","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.oret.2023.06.002_bib19","first-page":"782","article-title":"Polypoidal choroidal vasculopathy in Asians","volume":"4","author":"Wong","year":"2015","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.oret.2023.06.002_bib20","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1136\/bjo.2007.115501","article-title":"Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br","volume":"91","author":"Cohen","year":"2007","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0161-6420(00)00009-9","article-title":"Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration","volume":"107","author":"Slakter","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2023.06.002_bib22","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00417-007-0575-8","article-title":"Subtype lesions of neovascular age-related macular degeneration in Chinese patients","volume":"245","author":"Liu","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib23","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1016\/j.ophtha.2009.06.013","article-title":"Background comparison of typical age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients","volume":"116","author":"Ueta","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2023.06.002_bib24","article-title":"Relationship between pachychoroid and polypoidal choroidal vasculopathy","volume":"11","author":"Yamashiro","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.oret.2023.06.002_bib25","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1111\/aos.14756","article-title":"Efficacy and safety of different agents, dosages and strategies of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials","volume":"99","author":"Zhao","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib26","article-title":"Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): a systematic review and network meta-analysis of direct comparative studies","volume":"9","author":"Plyukhova","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.oret.2023.06.002_bib27","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2023.06.002_bib28","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2023.06.002_bib29","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2023.06.002_bib30","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2023.06.002_bib31","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bjophthalmol-2015-306987","article-title":"A\u00a0systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration","volume":"100","author":"Chin-Yee","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib32","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2023.06.002_bib34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/0301-4738.81023","article-title":"Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration","volume":"59","author":"Biswas","year":"2011","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133968","article-title":"Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA","volume":"10","author":"Ferreira","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.oret.2023.06.002_bib36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib37","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2023.06.002_bib38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.oret.2019.10.019","article-title":"Real-world treatment outcomes of age-related macular degeneration and polypoidal choroidal vasculopathy in Asians","volume":"4","author":"Fenner","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2023.06.002_bib39","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2023.06.002_bib40","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.2147\/OPTH.S275977","article-title":"Trends in real-world neovascular AMD treatment outcomes in the UK","volume":"14","author":"Mehta","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2023.06.002_bib41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ophtha.2007.02.031","article-title":"One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients","volume":"115","author":"Gomi","year":"2008","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302300252X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302300252X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T11:40:17Z","timestamp":1716291617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246865302300252X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S246865302300252X"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2023.06.002","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-VEGF Treatment Strategies for 3 Subtypes of Neovascular Age-Related Macular Degeneration in a Clinical Setting","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2023.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}